Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Osteoarthritis Cartilage. 2008 Jun 20;17(1):114–123. doi: 10.1016/j.joca.2008.05.006

Table 3.

Properties of constructs treated with TGF-β1 in phase I.

Group WW (mg) Thickness (mm) Total Cells (×106) FI
Control 24.9±2.8 0.88±0.14 5.7±0.3 0.60±0.08
30 ng/ml Continuous 12.6±0.7a 0.57±0.06a 6.6±0.4a 0.82±0.07a
30 ng/ml Wk Rotat. 13.9±0.6a 0.57±0.02a 6.5±0.8a 0.81±0.14a
10 ng/ml Continuous 17.8±1.3a 0.64±0.09a 5.7±0.4 0.62±0.07
10 ng/ml Wk Rotat. 17.9±4.6a 0.76±0.17 5.8±0.8 0.55±0.06
a

Significantly different from control

Wk Rotat., 2-wk rotation dosage; Col., total collagen